{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:47:07Z","timestamp":1760204827975,"version":"3.41.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Polish Ministry of Science and Higher Education","doi-asserted-by":"publisher","award":["0107\/IP1\/2013\/72"],"award-info":[{"award-number":["0107\/IP1\/2013\/72"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"crossref","award":["#503\/1-156-04\/503-01","502-03\/1-156-02\/502-14-141"],"award-info":[{"award-number":["#503\/1-156-04\/503-01","502-03\/1-156-02\/502-14-141"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["#UMO-2013\/11\/B\/NZ7\/01301","#UMO-2013\/11\/N\/NZ7\/00724","UMO-2014\/12\/T\/NZ7\/00252"],"award-info":[{"award-number":["#UMO-2013\/11\/B\/NZ7\/01301","#UMO-2013\/11\/N\/NZ7\/00724","UMO-2014\/12\/T\/NZ7\/00252"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.pharep.2015.06.001","type":"journal-article","created":{"date-parts":[[2015,6,14]],"date-time":"2015-06-14T02:48:22Z","timestamp":1434250102000},"page":"32-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mixed MOP\/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms"],"prefix":"10.1007","volume":"68","author":[{"given":"Marta","family":"Zieli\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Jarmu\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Sa\u0142aga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej W.","family":"Lipkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Fichna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"9","key":"10.1016\/j.pharep.2015.06.001_bib0160","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1365-2036.2004.01938.x","article-title":"Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population","volume":"19","author":"Locke","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"37","key":"10.1016\/j.pharep.2015.06.001_bib0165","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.3748\/wjg.v18.i37.5151","article-title":"Irritable bowel syndrome: diagnosis and pathogenesis","volume":"18","author":"El-Salhy","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.pharep.2015.06.001_bib0170","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1053\/bega.2002.0356","article-title":"Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments","volume":"16","author":"Hunt","year":"2002","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.pharep.2015.06.001_bib0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aep129","article-title":"Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile","volume":"103","author":"Dietis","year":"2009","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.pharep.2015.06.001_bib0180","first-page":"165","article-title":"Pain pharmacology: focus on opioids","volume":"11","author":"Fornasari","year":"2014","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"1","key":"10.1016\/j.pharep.2015.06.001_bib0185","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00535-013-0753-x","article-title":"Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives","volume":"49","author":"Sobczak","year":"2014","journal-title":"J Gastroenterol"},{"issue":"4077","key":"10.1016\/j.pharep.2015.06.001_bib0190","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1126\/science.179.4077.1011","article-title":"Opiate receptor: demonstration in nervous tissue","volume":"179","author":"Pert","year":"1973","journal-title":"Science"},{"issue":"5611","key":"10.1016\/j.pharep.2015.06.001_bib0195","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/267495a0","article-title":"Endogenous opioid peptides: multiple agonists and receptors","volume":"267","author":"Lord","year":"1977","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharep.2015.06.001_bib0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0163-7258(95)02053-5","article-title":"Insights into opioid action in the intestinal tract","volume":"69","author":"De","year":"1996","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pharep.2015.06.001_bib0205","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14740338.2014.902932","article-title":"The safety of novel drugs used to treat irritable bowel syndrome","volume":"13","author":"Mozaffari","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.pharep.2015.06.001_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568026043451618","article-title":"Opioid receptors and their ligands","volume":"4","author":"Janecka","year":"2004","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"10.1016\/j.pharep.2015.06.001_bib0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/jpet.114.214239","article-title":"Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome","volume":"350","author":"Salaga","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharep.2015.06.001_bib0220","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/jphp.12335","article-title":"Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome","volume":"67","author":"Zielinska","year":"2015","journal-title":"J Pharm Pharmacol"},{"issue":"12","key":"10.1016\/j.pharep.2015.06.001_bib0225","doi-asserted-by":"crossref","first-page":"11152","DOI":"10.1074\/jbc.M500171200","article-title":"Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions","volume":"280","author":"Law","year":"2005","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharep.2015.06.001_bib0230","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ana.22002","article-title":"How to design an opioid drug that causes reduced tolerance and dependence","volume":"67","author":"Berger","year":"2010","journal-title":"Ann Neurol"},{"issue":"49","key":"10.1016\/j.pharep.2015.06.001_bib0235","doi-asserted-by":"crossref","first-page":"16459","DOI":"10.1523\/JNEUROSCI.3748-10.2010","article-title":"Ligand-directed trafficking of the delta-opioid receptor in vivo: two paths toward analgesic tolerance","volume":"30","author":"Pradhan","year":"2010","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharep.2015.06.001_bib0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1742-7843.2005.pto_97107.x","article-title":"A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80","volume":"97","author":"Gallantine","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.pharep.2015.06.001_bib0245","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0196-9781(82)90173-5","article-title":"Double-enkephalins \u2013 synthesis activity on guinea-pig ileum, and analgesic effect","volume":"3","author":"Lipkowski","year":"1982","journal-title":"Peptides"},{"key":"10.1016\/j.pharep.2015.06.001_bib0250","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.peptides.2014.08.005","article-title":"Anti-inflammatory and antinociceptive action of the dimeric enkephalin peptide biphalin in the mouse model of colitis: new potential treatment of abdominal pain associated with inflammatory bowel diseases","volume":"60","author":"Sobczak","year":"2014","journal-title":"Peptides"},{"issue":"17","key":"10.1016\/j.pharep.2015.06.001_bib0255","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMra1207068","article-title":"Peripheral mechanisms in irritable bowel syndrome","volume":"367","author":"Camilleri","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharep.2015.06.001_bib0260","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1053\/j.gastro.2005.12.047","article-title":"Neuroendocrine and neuroimmune markers in IBS: pathophysiological role or epiphenomenon?","volume":"130","author":"Chang","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharep.2015.06.001_bib0265","first-page":"2783","article-title":"Irritable bowel syndrome: the role of gut neuroendocrine peptides","volume":"4","author":"El-Salhy","year":"2012","journal-title":"Front Biosci (Elite Ed)"},{"issue":"3","key":"10.1016\/j.pharep.2015.06.001_bib0270","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0022-3565(25)38254-6","article-title":"Antinociceptive profile of biphalin, a dimeric enkephalin analog","volume":"265","author":"Horan","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"3\/4","key":"10.1016\/j.pharep.2015.06.001_bib0275","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/BF01986590","article-title":"Analgesic activity of a novel bivalent opioid peptide compared to morphine via different routes of administration","volume":"33","author":"Silbert","year":"1991","journal-title":"Agents Actions"},{"issue":"3","key":"10.1016\/j.pharep.2015.06.001_bib0280","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1046\/j.1471-4159.1997.69031236.x","article-title":"Brain and spinal cord distribution of biphalin: correlation with opioid receptor density and mechanism of CNS entry","volume":"69","author":"Abbruscato","year":"1997","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.pharep.2015.06.001_bib0285","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0022-3565(25)12379-3","article-title":"Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives","volume":"276","author":"Abbruscato","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"10.1016\/j.pharep.2015.06.001_bib0290","doi-asserted-by":"crossref","first-page":"L199","DOI":"10.1016\/S0024-3205(98)00058-7","article-title":"[125I-Tyr1]biphalin binding to opioid receptors of rat brain and NG108-15 cell membranes","volume":"62","author":"Slaninova","year":"1998","journal-title":"Life Sci"},{"issue":"9","key":"10.1016\/j.pharep.2015.06.001_bib0295","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0192-0561(98)00052-6","article-title":"Inhibitory effect of biphalin and AZT on murine Friend leukemia virus infection in vitro","volume":"20","author":"Tang","year":"1998","journal-title":"Int J Immunopharmacol"},{"issue":"8","key":"10.1016\/j.pharep.2015.06.001_bib0300","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.peptides.2010.05.002","article-title":"A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro","volume":"31","author":"Lazarczyk","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.pharep.2015.06.001_bib0305","first-page":"1","article-title":"The non-opioid receptor, antioxidant properties of morphine and the opioid peptide analog biphalin","volume":"63C","author":"Garbuz","year":"2014","journal-title":"Peptides"},{"issue":"9","key":"10.1016\/j.pharep.2015.06.001_bib0310","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0024-3205(01)01194-8","article-title":"The opioid peptide analogue biphalin induces less physical dependence than morphine","volume":"69","author":"Yamazaki","year":"2001","journal-title":"Life Sci"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114015001152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114015001152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:09Z","timestamp":1752611769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2015.06.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1734114015001152"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2015.06.001","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mixed MOP\/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2015.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}